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Background
Omalizumab is a humanized antibody utilized for patients
with moderate/severe allergic asthma. There is an esti-
mated risk of anaphylaxis to omalizumab in 0.1% of
patients. Omalizumab should be received in the subcuta-
neous tissue of the mid-posterolateral upper arm. There
may be an increased risk of anaphylaxis if injections are
received intramuscularly (IM). In our clinic, omalizumab
is given with BD Eclipse™ Needle, which is routinely pro-
vided with the drug and has needle length 16mm. If a
patient has a skin to muscle depth (STMD) less than
16mm, there is a risk of omalizumab being injected IM.
Methods
We reviewed charts in an allergy clinic where an ultra-
sound of the left posterolateral arm was completed to
measure STMD. Patients were divided into two groups
based on their STMD (>16mm and ≤16mm) and baseline
characteristics were compared. We conducted multivari-
able linear regression with age, sex, BMI and race. The
percentages of patients with STMD greater than 4mm,
6mm, 8mm, 10mm, and 12mm were determined.
Results
Ultrasounds were completed on 40 patients receiving
omalizumab. Three (7.5%) patients examined had >16mm
of STMD. Baseline characteristics were consistent between
the groups except for BMI (p < 0.05). Sex and BMI corre-
lated with STMD based on the linear regression analysis.
Also, 35 (87.5%) patients had >4mm STMD.
Conclusion
With provided omalizumab needles, the risk of anaphy-
laxis may be increased as the injections may be given IM.
By reducing the needle length to 4mm, the risk will likely
be reduced.
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